These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36963335)

  • 81. COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks.
    Liu S; Yu Y; Wang Y; Zhu B; Han B
    Eur J Med Res; 2022 Jul; 27(1):122. PubMed ID: 35842702
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.
    Yu J; Mao W; Xu B; Chen M
    Cancer Med; 2021 Apr; 10(7):2359-2369. PubMed ID: 33650306
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pan-cancer profiles of the cuproptosis gene set.
    Liu H
    Am J Cancer Res; 2022; 12(8):4074-4081. PubMed ID: 36119826
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comprehensive analysis of MFN2 as a prognostic biomarker associated with immune cell infiltration in renal clear cell carcinoma.
    Cheng L; Wang Z; Nie L; Yang C; Huang H; Lin J; Zhuo D
    Int Immunopharmacol; 2022 Oct; 111():109169. PubMed ID: 36007389
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Bioinformatics analysis of markers based on m
    Liu L; Zhuang M; Tu XH; Li CC; Liu HH; Wang J
    Cell Biol Int; 2023 Jan; 47(1):260-272. PubMed ID: 36200528
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
    Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
    Front Immunol; 2022; 13():998236. PubMed ID: 36110851
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma.
    Jiang H; Chen H; Wan P; Chen N
    Genomics; 2021 Nov; 113(6):3556-3564. PubMed ID: 34391866
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
    Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
    Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Metabolic Understanding of the Genetic Dysregulation in the Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma.
    Xie J; Cui L; Pan S; Liu D; Liu F; Liu Z
    Dis Markers; 2022; 2022():6085072. PubMed ID: 35096203
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
    Yang Q; Zeng S; Liu W
    PeerJ; 2023; 11():e15019. PubMed ID: 36949759
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.
    Li J; Yu T; Sun J; Zeng Z; Liu Z; Ma M; Zheng Z; He Y; Kang W
    Aging (Albany NY); 2023 Apr; 15(7):2772-2796. PubMed ID: 37036489
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis.
    Xie L; Wu S; He R; Li S; Lai X; Wang Z
    Front Immunol; 2022; 13():901662. PubMed ID: 36059531
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
    Luo L; Li A; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Yunpeng Y; Li Z; Hong S
    Immunol Res; 2023 Apr; 71(2):213-228. PubMed ID: 36434349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.